Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma
Rhenium (186Re) Obisbemeda demonstrates safety, response, and potential efficacy for glioblastoma (GBM) patients
Patients receiving >100 Gy of Rhenium (186Re) Obisbemeda achieved a median overall survival of 17 months, more than double the 8-month median overall survival with standard of care
HOUSTON, March 07, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ('Plus' or the 'Company'), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces the publication of results in a peer-reviewed manuscript titled, "Treatment of Recurrent Glioma by Rhenium (186Re) Obisbemeda (186RNL): a Phase 1 clinical trial" in the peer-reviewed medical journal Nature Communications.
'Peer-reviewed publication of our Phase 1 glioma data in a prestigious, high-impact factor journal is substantial validation for this important clinical program,' said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. 'Based largely on this data, our ReSPECT-GBM Phase 2 trial is currently enrolling patients at leading medical centers, bringing us closer to delivering a much-needed treatment option for this devastating disease.'
Key highlights from the publication:
Twenty-one patients were treated with doses up to 22.3 mCi of Rhenium (186Re) Obisbemeda
No dose-limiting toxicity was observed, and most adverse events were unrelated to the study treatment
Median overall survival (OS) was 11 months, surpassing the standard of care for recurrent glioblastoma, which is approximately 8 months
Median OS was strongly correlated with radiation absorbed dose to the tumor and the percentage of tumor treated
Patients receiving >100 Gy (n=12) had a median OS of 17 months, compared to 6 months for those receiving <100 Gy (n=9) (p=0.001)
Absorbed radiation doses to the tumor were as high as 739.5 Gy and were delivered without significant toxicity, exceeding levels achievable with external beam radiation therapy
The full manuscript can be accessed here.
The ReSPECT-GBM trial is actively enrolling patients; additional information about the ReSPECT-GBM trial can be found here.
About Recurrent Glioblastoma (GBM)
GBM affects approximately 15,000 patients annually in the U.S. and is the most common and lethal form of brain cancer. The average life expectancy with GBM is less than 24 months, with a one-year survival rate of 40% and a five-year survival rate of around 5%. There is no clear standard of care for recurrent GBM and the few currently approved treatments provide only marginal survival benefit and are associated with significant side effects, which limit dosing and prolonged use. Approximately 90% of patients experience GBM tumor recurrence at or near the original tumor location, yet there are no FDA-approved treatments in the recurrent or progressive setting that can significantly extend a patient's life.
About Rhenium (186Re) Obisbemeda
Rhenium (186Re) Obisbemeda is a novel injectable radiotherapy specifically formulated to deliver direct targeted high dose radiation in CNS tumors in a safe, effective, and convenient manner to optimize patient outcomes. Rhenium (186Re) Obisbemeda has the potential to reduce off target risks and improve outcomes for CNS cancer patients, versus currently approved therapies, with a more targeted and potent radiation dose. Rhenium-186 is an ideal radioisotope for CNS therapeutic applications due to its short half-life, beta energy for destroying cancerous tissue, and gamma energy for real-time imaging. Rhenium (186Re) Obisbemeda is being evaluated for the treatment of recurrent glioblastoma and leptomeningeal metastases in the ReSPECT-GBM and ReSPECT-LM clinical trials. ReSPECT-GBM is supported by an award from the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), and ReSPECT-LM is funded by a three-year $17.6M grant by the Cancer Prevention & Research Institute of Texas (CPRIT).
About Convection-Enhanced Delivery
Convection Enhanced Delivery (CED) is a therapeutic strategy that was developed to facilitate targeted delivery of pharmaceuticals to the brain. The CED procedure involves a minimally invasive surgical exposure of the brain, followed by placement of small diameter catheters directly into the brain tumor.
About Plus TherapeuticsPlus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. Plus Therapeutics is led by an experienced and dedicated leadership team and has operations in key cancer clinical development hubs including Austin and San Antonio, Texas. For more information, visit https://plustherapeutics.com/.
Cautionary Statement Regarding Forward-Looking StatementsThis presentation contains statements that may be deemed 'forward-looking statements' within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as 'potential,' 'anticipating,' 'planning' and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of Rhenium (186Re) Obisbemeda including the ability of Rhenium (186Re) Obisbemeda to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company's future performance including the next steps in developing the Company's current assets; the Company's clinical trials including statements regarding the timing and characteristics of the ReSPECT-GBM, ReSPECT-LM and ReSPECT-PBC, clinical trials; possible negative effects of Rhenium (186Re) Obisbemeda; the continued evaluation of Rhenium (186Re) Obisbemeda including through evaluations in additional patient cohorts; the intended functions of the Company's platform and expected benefits from such functions; and the development, utility and potential of the CNSide leptomeningeal metastases diagnostic test.
The forward-looking statements included in this press release could differ materially from those expressed or implied by these forward-looking statements because of risks, uncertainties, and other factors that include, but are not limited to, the following: the early stage of the Company's product candidates and therapies, the results of the Company's research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company's liquidity and capital resources and its ability to raise additional cash, the outcome of the Company's partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field, ability to develop and protect proprietary intellectual property or obtain licenses to intellectual property developed by others on commercially reasonable and competitive terms, and material security breach or cybersecurity attack affecting the Company's operations or property. This list of risks, uncertainties, and other factors is not complete. Plus Therapeutics discusses some of these matters more fully, as well as certain risk factors that could affect Plus Therapeutics' business, financial condition, results of operations, and prospects, in its reports filed with the SEC, including Plus Therapeutics' annual report on Form 10-K for the fiscal year ended December 31, 2023, quarterly reports on Form 10-Q, and current reports on Form 8-K. These filings are available for review through the SEC's website at www.sec.gov. Any or all forward-looking statements Plus Therapeutics makes may turn out to be wrong and can be affected by inaccurate assumptions Plus Therapeutics might make or by known or unknown risks, uncertainties, and other factors, including those identified in this press release. Accordingly, you should not place undue reliance on the forward-looking statements made in this press release, which speak only as of its date. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor ContactCharles Y. Huang, MBADirector of Capital Markets and Investor RelationsOffice: (202)-209-5751 | Direct (301)-728-7222chuang@plustherapeutics.comSign in to access your portfolio
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Roll-to-Roll Technologies for Flexible Devices Set to Grow at 11.5% CAGR
"Comprehensive Market Analysis Highlights Key Drivers, Emerging Technologies, and Competitive Landscape for Roll-to-Roll Technologies in Flexible Devices" Boston, June 10, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, the 'Global Markets for Roll-to-Roll Technologies for Flexible Devices' is expected to reach $69.8 billion by the end of 2029 at a compound annual growth rate (CAGR) of 11.5% from 2024 to 2029. The report offers an in-depth analysis of roll-to-roll (R2R) technologies for flexible devices, covering various device types and fabrication processes. It identifies current and emerging devices and provides detailed market segmentation by process category, substrate material, deposition method, end-use industry and region. The report includes a technological review of the fabrication steps and highlights the most active research organizations in this field and their activities. The rapid advancements in flexible electronics provide valuable insights into the market size, growth trends, players and emerging applications of R2R technologies. The report highlights the increasing demand for flexible and wearable devices, driving the adoption of R2R technologies for cost-effective, high-volume production. Additionally, the rising demand for R2R-produced solar cells and flexible devices in consumer electronics, optoelectronics and the automotive industry makes this report particularly timely and vital. The factors driving the market include: Demand for Flexible Devices: Flexible devices are increasingly popular in consumer electronics (like foldable phones), optoelectronics (such as OLED displays), and the automotive industry (for smart sensors and displays). They offer portability, durability, and innovative designs. Rising Demand for R2R-Produced Solar Cells: Roll-to-Roll technology enables cost-effective, flexible solar panels. These are crucial for renewable energy solutions, making solar power more accessible and versatile. Request a sample copy of the global market for R2R technologies for flexible devices report. Report Synopsis Report Metric Details Base year considered 2023 Forecast period considered 2024-2029 Base year market size $37.0 billion Market size forecast $69.8 billion Growth rate CAGR of 11.5% for the forecast period of 2024-2029 Segments covered Process category, substrate material, deposition method, end-use industry, and region Regions covered North America, Europe, Asia-Pacific, and the Rest of the world Countries covered The U.S., Canada, the U.K., Germany, France, Italy, China, India, Japan, Taiwan, and the Middle East and Africa Market drivers Growing demand for flexible devices across consumer electronics, optoelectronics and the automotive industry. Rising demand for R2R-produced solar energy and solar cells globally. Interesting facts: According to the Taiwan Printed Circuit Association (TPCA) and the Industrial Technology Research Institute (ITRI), in 2023, Taiwanese companies are the leading suppliers of flexible Printed Circuit Boards (PCBs), accounting for approximately 34.5% of the total market value. The U.S. accounted for more than 71% of the North American R2R technologies for flexible devices market. Asia-Pacific is expected to grow at the fastest CAGR of 12.8% from 2024 to 2029. In 2024, Several Indian companies, including Dixon Technologies, expanded their production capacities to cater to the growing demand for flexible devices. Dixon is expected to invest $176.7 million to $ 212.1 million in the next three years to expand its production capacity and component manufacturing. Emerging startups: GraphenicaLab: Founded in 2016, GraphenicaLab, a spin-off of Barcelona's Catalan Institute of Nanoscience and Nanotechnology (ICN2), leverages a patented state-of-the-art technology to print flexible graphene sensors and electronic devices directly onto various surfaces. GraphenicaLab has leveraged the extraordinary properties of graphene- the world's thinnest, lightest and strongest material. Delft Circuits BV: Founded in 2016, Delft Circuits provides hardware solutions for quantum engineers and industries. Delft has established itself as a trusted provider of cutting-edge quantum technology with hundreds of I/O modules delivered to nearly a hundred clients, including leading national laboratories, blue-chip corporations, and ambitious academic researchers. The report addresses the following questions: What is the projected market size and growth rate of the global market R2R technologies for flexible devices? The market was valued at $37.0 billion in 2023 and will reach $69.8 billion by the end of 2029, growing at a CAGR of 11.5% from 2024 to 2029. What factors are driving the growth of the R2R technologies for flexible devices market? The growing demand for flexible devices across consumer electronics, optoelectronics, and the automotive industry. Rising demand for R2R-produced solar energy and solar cells. Which end-use industry segment will dominate the market by the end of 2029? The consumer electronics segment will continue to dominate the market. Which region has the largest market share in the global R2R technologies for flexible devices market? The Asia-Pacific region has the largest share in the global market. Leading companies in the market include: 3M ALL FLEX SOLUTIONS APPLIED MATERIALS INC. ASCENT SOLAR TECHNOLOGIES INC. AUO CORP. CAREER TECHNOLOGY (MFG.) CO. LTD. E INK HOLDINGS INC. FLEXIUM INTERCONNECT INC. FUJIKURA LTD. HELIATEK INTERFLEX CO. LTD. JOHNSON ELECTRIC HOLDINGS LTD. MOLEX PANASONIC HOLDINGS CORP. SAMSUNG SUMITOMO ELECTRIC INDUSTRIES LTD. Related reports include: Advanced Materials for 3D Printing: Technologies and Global Markets: The report comprehensively analyzes the global market for advanced materials used in 3D printing. It examines the market by material (plastics and polymers, metals), technology (vat polymerization, powder bed fusion, material extrusion), end-user industries (transportation, medical and dental, consumer products and electronics, industrial machinery), and region (Asia-Pacific, Europe, North America, the Rest of the World). Printed Circuit Boards: Technologies and Global Markets: The report analyzes current trends in the global market for printed circuit boards (PCBs). It covers global revenue for five market segments (assembly technology, PCB type, PCB structure, PCB thickness and end-user industry) across four regions (North America, Europe, Asia-Pacific, and the Rest of the World). The report explores growth drivers and challenges of the market, leading PCB manufacturers, emerging technologies, competitive and technological differentiators, and environmental, social, and governance (ESG) developments in the industry. Navigate Uncertainty with ConfidenceIn times of rapid change and uncertainty, having the right insights can make all the difference. At BCC Research, we are here to support innovation and help you stay ahead. Our custom research reports provide a comprehensive, 360-degree view of your market landscape, giving you the clarity you need to make informed decisions. We believe that timely, expert market intelligence should be accessible to all. That is why, for a limited time, we are offering 30% off the price of any BCC Research report to help more organizations gain access to our latest data and insights. Purchase a copy of the report directly from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. CONTACT: BCC Research Corporate HQ: 50 Milk St. Ste 16, Boston, MA 02109, USA Email: info@ Phone: +1 781-489-7301Sign in to access your portfolio
Yahoo
30 minutes ago
- Yahoo
Success Story Podcast Announces New Episode Featuring Billionaire Grant Cardone on Wealth and Leadership
Billionaire Real Estate Mogul Grant Cardone Reveals Why He "Should Be Worth $20 Billion Today" and Shares Unconventional Success Blueprint $4 Billion Empire Builder Discusses Breaking Comfort Zone Addiction, Choosing the Right "Vehicle" for Wealth, and Why Most People Have "Quit on Money" Cardone also hints at major announcement coming "within the week" and reconsiders California political ambitions Miami, Florida , June 10, 2025 (GLOBE NEWSWIRE) -- Success Story Podcast, hosted by Scott Clary, has announced a new episode featuring billionaire entrepreneur and Cardone Ventures CEO Grant Cardone. In this exclusive conversation, Cardone shares unfiltered insights on building generational wealth, the hidden challenges of leadership, and the mindset shifts that separate top performers from the rest. The episode offers listeners a candid look at Cardone's personal journey and practical strategies for achieving extraordinary success. Grant Cardone, the outspoken billionaire behind a $4 billion real estate empire and bestselling author of "The 10X Rule," delivered hard-hitting insights about wealth creation, leadership isolation, and the critical decisions that separate the ultra-successful from everyone else in a revealing interview on Scott Clary's Success Story podcast. The $20 Billion Revelation In a candid moment, Cardone stated he "should be worth $20 billion today," attributing the gap to strategic vehicle choices rather than effort or mindset. "The difference between me and my friend who gained $9 billion in two weeks isn't the mindset – we both want abundance and to help millions of people. The difference is the vehicle," Cardone explained, referencing a friend who recently experienced massive volatility, gaining $5 billion in one day before losing $6 billion the following Friday. The Comfort Zone Trap Cardone identified "comfort" as a dangerous addiction that prevents breakthrough success. "Comfortable is a serious addiction that allows you to socially drift through life. You're on a drug of 'I don't want to take risk, I don't want to feel stressed, I just want enough,'" he warned. He revealed that even after making his first million dollars, he fell into this trap: "I went into conservation mode, not hunger mode. What I should have done is 10X that million." Why Most People Have "Quit on Money" Addressing widespread financial struggles, particularly citing Toronto's housing crisis where million-dollar condos are unattainable for $70K earners, Cardone argued that most people have psychologically given up on wealth creation. "I think most people have quit on the money game. They're like, 'I'm not going to have it. The game's rigged. I just need to be happy,'" he observed. His solution is radical target-setting: "Your target should be monster. Make a 100X exit. Then find out whether the business you're in right now can actually get you to that target." The Leadership Loneliness Factor Cardone opened up about the isolation that comes with high-level decision-making, comparing his experience to Donald Trump's situation. "Do you know how lonely Donald Trump must be? There is no way that guy's doing what he's doing on a daily basis that he gets support from everybody around him," he reflected. "If you're in a leadership position, you're going to be in a situation one day where you got to go take a hill and you're going to look up – you're by yourself." Controversial Education and Parenting Philosophy The billionaire continued his criticism of traditional education paths, stating most people "should not go to college" and calling the current system "insanity." For parenting, he advocates extreme engagement: "You cannot turn them over to YouTube and Facebook. Those are not nannies. Get your kids off TV, get your kids off YouTube, get your kids active." Cardone homeschools his children year-round and requires them to work under contract since age six, resulting in his 15-year-old daughter graduating high school at 15. Political Ambitions in Question In a rare moment of uncertainty, Cardone revealed he's "second-guessing the whole California thing," referring to his consideration of entering California politics to "flip it red." Despite believing he "could win it," he's questioning whether to pursue the opportunity given other priorities. The Ultimate Success Formula When asked for the single most important lesson he'd pass to his children, Cardone delivered his core philosophy: "You will never get anything great without leaving something good." About Success Story Podcast The Success Story podcast, hosted by Scott Clary, features in-depth conversations with the world's most successful entrepreneurs, investors, and business leaders. Known for extracting actionable insights and candid revelations, the show has become a premier destination for ambitious professionals seeking real-world business wisdom. Watch the full interview: About Grant Cardone Grant Cardone is a New York Times bestselling author, sales expert, real estate investor, and entrepreneur who has built a $4 billion real estate portfolio. He is the founder and CEO of Cardone Capital and Cardone Ventures, and the author of several business books including "The 10X Rule." Known for his no-nonsense approach to business and wealth building, Cardone has trained Fortune 500 companies and speaks to hundreds of thousands annually about sales, business, and success strategies. About Success Story Podcast The Success Story Podcast is hosted by entrepreneur, business executive, author, educator and speaker Scott D. Clary. On Success Story, he conducts candid conversations with some of the most prolific business and thought leaders in the world. The podcast ranks as a Top 10 business podcast and Top 3 Education/Self Development podcast, with over 50 million downloads. It is part of the HubSpot Podcast Network and Cheddar. Clary's weekly business newsletter reaches over 321,000 subscribers, sharing valuable insights from his experiences throughout his career. Press inquiries Success Story Podcast Scott D. Clary scott@ A video accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
35 minutes ago
- Yahoo
The 2025 MISTRs Are Here — and They're Hotter Than Free Online PrEP
From viral creators to queer heartthrobs, this year's MISTRs are serving face, body, and free sexual healthcare for all The 2020 MISTRs MISTR: Free online PrEP, DoxyPEP & STI Testing Miami, FL, June 10, 2025 (GLOBE NEWSWIRE) -- Things just got hotter. MISTR, the nation's #1 LGBTQ+ telehealth platform for sexual health, is proud to unveil the new class of MISTRs for 2025 — twelve bold, beautiful, and totally unfiltered ambassadors who are bringing free sexual healthcare to your feed and your bedroom. Serving more than 500,000 patients served nationwide, MISTR makes it easy to stay protected. Patients can sign up online for PrEP — a once-a-day pill that reduces the risk of HIV by 99% — and DoxyPEP, an antibiotic taken after sex that helps prevent common STIs like syphilis, chlamydia, and gonorrhea. When bundled together, they offer next-level protection — and MISTR makes it 100% free, fast, and delivered discreetly to your door. 'Being a MISTR means showing up — shirtless, fearless, and fully protected,' said Tristan Schukraft, Founder and CEO of MISTR. 'These guys are fun, fearless, and fully committed to making HIV prevention sexy and stigma-free.' This year's lineup includes digital disruptors, fitness kings, and unapologetically queer content creators — including model and LGBTQ+ heartthrob Bruno Alcantara and the sizzling creator and advocate Kyle Krieger — all teaming up with MISTR to spread the word (and maybe more). Each MISTR will appear in exclusive video content, social collabs, and events promoting MISTR's 100% free online access to PrEP, DoxyPEP, STI testing, and long-term HIV care – all available online at with or without insurance. The full 2025 MISTR roster: Bruno Alcantara Harold Cabrera Ruiz Chase Carlson Christian Dante White Dany Juvier Kyle Krieger Jordan Lipes David Oberto Robert Pérez Ty Talley Doryin Thames Dru Vu Together, they'll be showing the world that taking care of your sexual health doesn't have to be boring, awkward, or expensive. It can be hot, fast, free, and delivered to your door. Follow the campaign at @heymistr, and visit to get on PrEP or DoxyPEP with zero cost, zero judgment, and zero excuses. # # # ABOUT MISTRMISTR is a telemedicine platform offering free online access to pre-exposure prophylaxis (PrEP) DoxyPEP, STI Testing and long-term HIV care in all 50 states, D.C. and Puerto Rico. Gay owned and operated, MISTR has brought together a network of the best doctors, pharmacists, and problem solvers to make PrEP, DoxyPEP and long-term HIV care available to all who need it. No doctor's office, no paperwork and free delivery. Learn more at Attachments The 2020 MISTRs MISTR: Free online PrEP, DoxyPEP & STI Testing CONTACT: Brian Rosman MISTR 323.443.7780 mistr@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data